When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options Medical Education on ReachMD

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Educational information
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Faculty
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Recommended

Details

Presenters

Overview
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Educational information
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Faculty
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options